Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...

It is scary.” Periodic Paralysis has three common types: Hyperkalemic, Hypokalemic, and Andersen-Tawil syndrome. It is being recognized on Rare Disease Day on Friday. Established in 2008 by ...

The first time Dr. Fajgenbaum repurposed a drug, it was in an attempt to save his own life. At 25, while in medical school, ...

since up to this time there has been a rather clear separation between the agents that benefit each syndrome. Heretofore, what was effective therapy for one type of periodic paralysis has ...

Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...

Anecdotal evidence has long suggested that sleep problems are especially common for people with Moebius syndrome. Now, a new ...

Xeris Biopharma Holdings, Inc. , a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, ...

Xeris has three commercially available products: Recorlev®, for the treatment of endogenous Cushing’s syndrome ... a proven therapy for primary periodic paralysis. Xeris also has a pipeline ...

and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.